Loviride
From Self-sufficiency
| File:Loviride.png | |
| Systematic (IUPAC) name | |
|---|---|
|
2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide | |
| Identifiers | |
| ATC code | none |
| PubChem | CID 3963 |
| Synonyms | R089439 |
| Chemical data | |
| Formula | C17H16Cl2N2O2 |
| Molar mass | 351.227 g/mol[[Script error: No such module "String".]] |
Loviride (also called Loveride[citation needed]) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials Loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.
External links
| 50px | This antiinfective drug article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from February 2010
- Articles with invalid date parameter in template
- Antiretroviral drugs
- Organochlorides
- Acetamides
- Aromatic ketones
- Antiinfective agent stubs
- 2Fix
